


Company

NanoCarrier Co., Ltd.





Presenter

Kenichiro
NaitoMicellar Nanoparticle

PEG + polyamino acid

Self-assembled micelle of 30-100 nm size
consisting of amphiphilic polymers


Clinical Pipeline

Product	Cancer Indication	BR	PC	ph1	ph2	ph3	Develop Area	Alliance Partner
NC-6004 Cisplatin micelle	Pancreatic	Co-Development					Japan/Asia	 友華股份有限公司 Orient Europharma Co., Ltd.
	Lung (NSCL) Bladder Biliary tract	In-House Development					USA/EU	
	Head and neck	Co-Development					USA/EU /Asia	 友華股份有限公司 Orient Europharma Co., Ltd.
NC-6300 Epirubicin micelle	Soft tissue sarcoma	In-House					USA	
NC-4016 Dach-platinum micelle	Solid	In-House					USA	
NK105 (Out-Licensed) Paclitaxel micelle	Breast Gastric	Out-Licensed					Japan	Global "Sukima" Ideas  NIPPON KAYAKU
VB-111 (In-Licensed) Non-replicating Adeno 5 vectors	Ovarian Thyroid	In-Licensed					Japan	Vector Biotech Inc. (operating as...)
		VBL					(Mainly in USA)	 VBL therapeutics

Next Generation Technology

Active targeting: ADCM

Deliver payloads (small molecular weight compounds, nucleic acids, peptides, protein) directly into target cells



The combination of payload in the micelle and sensor on the surface of the micelle enables to develop a new therapeutics for a variety of diseases.

Discovery of new drugs to meet medical care needs

Other companies/Research organizations, etc.



- New drug candidates
- Existing drugs
- Compounds abandoned at development stage
- ADCs

Seeking to enhance performance through unique formulation technologies

- Targeting
- Safety
- Solubility
- Pharmacokinetics
- Efficacy